Loyal

Phase A — Understand the business

Lens 1 · Company Overview

Loyal is a clinical-stage veterinary-pharma company developing the first drugs explicitly intended to extend healthy lifespan (healthspan + lifespan) in dogs by targeting underlying mechanisms of aging, rather than treating a single disease. Founded 2019 by Celine Halioua (then 25), who had been Chief of Staff to Laura Deming at The Longevity Fund before leaving an Oxford D.Phil. (health economics of gene therapy) to start it. HQ San Francisco; in-house manufacturing being stood up in Denver.

The business model, plainly: Loyal is a single-vertical drug developer with a recurring-revenue consumer-health endgame. The thesis: dogs are a better aging model than mice — they share human environments, develop analogous age-related disease, and (critically) have short enough lifespans to run a real lifespan-endpoint trial in years, not decades. Loyal monetizes through prescription drugs sold via the veterinary channel on a monthly subscription ("less than $100/month for daily pills"), with stated gross margins >50% off the Denver tableting line, plus optional companion-diagnostics/biomarker revenue off its trial database.

• Product / service today: None commercial yet. No approved product, no revenue disclosed. The company is pre-launch, working through FDA conditional-approval technical sections.
• Lead products (pipeline = the company, see Lens 5):
• LOY-002 — daily flavored oral tablet, senior dogs ≥10 yr and ≥14 lb, targets metabolic dysfunction as an aging driver; a caloric-restriction mimetic.
• LOY-001 — long-acting injectable, large/giant breeds, reduces IGF-1 toward the levels of smaller, longer-lived dogs.
• LOY-003 — oral pill version of the LOY-001 IGF-1 mechanism for large/giant breeds.
• Customers: dog owners, reached only via licensed veterinarians — prescription-only, no direct-to-consumer online channel.
• Suppliers: API/excipient suppliers not disclosed; Loyal is vertically integrating tableting in Denver to control cost and supply (the notable structural choice).
• Contract structure / payment terms: the revenue structure that matters is recurring monthly subscription through the vet — predictable, annuity-like, but gated entirely on FDA approval which does not yet exist.

Lens 2 · Supply Chain

For a pre-launch drug company the chain is a clinical-infrastructure + manufacturing chain. Mapping with named/named-class stakeholders:

Upstream (inputs Loyal consumes):

• Capital — Khosla Ventures, First Round Capital, Bain Capital Ventures, Valor Equity Partners, Box Group, Collaborative Fund, Quiet Capital, Todd & Rahul's Angel Fund, age1 (Laura Deming), Baillie Gifford; debt from Bridge Bank / Western Alliance (a $12M credit facility).
• Scientific inputs / IP origin — the caloric-restriction-extends-lifespan evidence base (the canonical Purina lifetime-feeding study: calorie-restricted Labradors lived ~1.8 yr longer with delayed disease onset) and the IGF-1/body-size aging literature underpin the two mechanisms. Loyal's own X-Thousand Dogs epigenetic study (>2,000 dogs, methylation-clock biomarkers) is a proprietary upstream data asset.
• Clinical infrastructure — ~70 independent veterinary clinics nationwide running the STAY trial; 1,300 client-owned dogs enrolled. This is the upstream that competitors can't cheaply replicate.

Midstream (Loyal itself): drug development + regulatory + the Denver tableting facility (in-house manufacturing — the deliberate vertical-integration move that drives the >50% gross-margin claim).

Downstream (does not yet exist at scale):

• Distribution chokepoint = the veterinarian. Every dose flows through a prescribing vet — Loyal must win clinic adoption against the incumbents who own those relationships (Zoetis, Elanco, Boehringer Ingelheim).
• Regulatory chokepoint = the FDA Center for Veterinary Medicine (CVM). The single most important downstream gate; the product cannot be sold until the third technical section (CMC/manufacturing) clears (Lens 5/11).

Provenance caveat: no API supplier or CDMO is publicly named; the Denver in-house line and the 70-clinic network are the disclosed, distinctive nodes. Class-level incumbents named from the animal-health market structure, labeled ``.

Lens 3 · Competitive Advantages (moats)

What's genuinely defensible:

1. Regulatory first-mover / category-definition. Loyal is the first sponsor the FDA has engaged on a "lifespan extension" claim — RXE accepted for LOY-001 (Nov 2023) and LOY-002 (Feb 2025). This built the regulatory pathway itself (the application of the MUMS/conditional-approval framework to a longevity indication). A follower has to walk a path Loyal cleared — real, if soft, moat.
2. The clinical dataset. The STAY study — 1,300 dogs, ~70 clinics, the largest trial in veterinary-medicine history — plus the X-Thousand Dogs epigenetic corpus is a data asset that is expensive and slow to reproduce. In an evidence-thin field, owning the largest dataset is the durable edge.
3. Brand + founder magnetism in longevity. Halioua is among the most visible operators in the field; Loyal pulled capital from investors who wanted human longevity but couldn't wait decades — i.e. it captured longevity-dedicated money (age1/Deming, Baillie Gifford) into a vehicle with a near-term readout.

Bargaining power: As a future seller, Loyal has none yet — no approval, no pricing power, and it must rent the incumbents' distribution channel (the vet). Its leverage with owners would come from being the only FDA-labeled lifespan drug — a genuine differentiator if approval lands.

Net: the moat is regulatory-pathway ownership + the largest clinical dataset + brand — defensible but entirely contingent on the STAY readout and FDA approval. Pre-approval, it is a moat around an asset that hasn't proven it works. [Ground: positioning.md / bottlenecks.md both missing — this lens is web+estimate only.]

Lens 4 · Segments

n/a — no revenue to segment. The meaningful segmentation is by program / target population:

. The trend that matters: resource and regulatory momentum are concentrated on LOY-002 (broadest addressable population — any breed ≥14 lb — and furthest through the FDA). LOY-002 is the value driver; LOY-001/003 are the breadth optionality.

---

Phase B — Measure performance (+clinical / +private overlay: pipeline · funding trajectory · traction)

Lens 5 · Pipeline by phase + Funding & valuation trajectory

Pipeline by phase (the +clinical core lens — the asset table is the company):

. Hard read: LOY-002 has cleared two of the three technical sections the FDA requires for an Expanded Conditional Approval (XCA) — Reasonable Expectation of Effectiveness (RXE) and Target Animal Safety (TAS) — leaving only the CMC/manufacturing section. Under conditional approval Loyal could market while the full STAY effectiveness data matures. The crucial nuance the bull case glosses: RXE is a "reasonably expected to be effective" bar, not "substantial evidence of effectiveness" — the lifespan endpoint itself reads out years later (Lens 13).

Funding & valuation trajectory (the +private core lens):

• Round history (disclosed):
• Early rounds incl. a ~$27M Series A-era and seed (Khosla, First Round, Box Group, Collaborative, Quiet).
• Series B — $45M, Mar 2024, led by Bain Capital Ventures (Valor new; Khosla, First Round et al. participating).
• Series B-2 — $22M, Feb 2025, led by Valor Equity Partners (with a $12M Bridge Bank credit facility, bringing cumulative to "over $125M").
• Series C — $100M, announced 11 Feb 2026, led by age1 (Laura Deming's "next-generation" Longevity Fund), with Baillie Gifford participating.
• Cumulative total — CONFLICTED, flag: Sacra reports ~$150M total (as of 2025); the company's own Series-C era framing and founder bio cite "$250M+ raised". Reconciliation: ~$150M prior + the $100M Series C ≈ ~$250M cumulative — the two figures are likely a pre- vs post-Series-C timing artifact, not a contradiction. I anchor on "~$150M pre-Series-C, ~$250M+ inclusive." A third tracker cited "$155M" (pre-C).
• Valuation: n/a — not disclosed. No priced valuation is public for any round; secondary marks not found. Refusing to fabricate one.
• Burn / runway: n/a — not disclosed. A $100M Series C explicitly earmarked for "final regulatory work, scientific platform, team expansion, and commercial-launch prep" signals Loyal is funding through approval + launch — i.e. the raise is sized to reach the value-inflection (Lens 11). The crossover-style Baillie Gifford entry at Series C is a maturation/IPO-proximity tell (Lens 7).

Lens 6 · Founder / leadership signal (sentiment trend — +private swap for earnings calls)

No earnings calls. Proxy = what leadership says and how milestones land:

• Founding tone (2019–2022): mission-first, "extend healthy lifespan," dogs-as-the-better-model framing.
• 2023–2026 shift: distinctly more regulatory-execution and commercial — language moves from "we're researching aging" to "first FDA-approved lifespan extension drug," "two of three sections complete," "preparing for commercial launch". The recurring new phrase is "FDA approval / launch"; the thing said less is open-ended science.
• The unmistakable signal: Halioua publicly framing each FDA section acceptance as a countable step ("2 of 3 major sections complete") and the largest-trial-ever milestone is a disciplined, de-risking, investor-legible narrative — bullish on execution credibility. The risk: it sets a public expectation of approval that a CMC delay or a soft STAY readout would puncture loudly.

Lens 7 · Catalyst calendar + mechanism comps (+clinical/+private swap for the P/E comp table)

Catalyst calendar (what de-risks or kills, and when):

Mechanism comps (by target/approach — there is no P/E):

The comp verdict: On the only comp that scores — distance to an FDA lifespan label — Loyal is alone at the front. The nearest scientific rival (Dog Aging Project's TRIAD) is an academic study, not a commercial drug program, and rapamycin's canine lifespan data is still maturing. TriviumVet and Cat Health are different species/indications. Loyal's lead is structural (it built the pathway), not just temporal — but "first" is only valuable if STAY ultimately shows the lifespan benefit.

Lens 8 · Catalysts that moved the story (funding/product events — +private swap)

With no stock, "what moved the narrative":

• Nov 2023 — FDA RXE for LOY-001 (large dogs): the field-defining event — first time the FDA signaled willingness to entertain a lifespan claim.
• Feb 2024 — STAY trial launches (1,000-dog target, later 1,300): largest vet trial in history; credibility leap.
• Mar 2024 — $45M Series B (Bain lead): institutional validation.
• Feb 2025 — FDA RXE for LOY-002 (senior dogs, broad): moved the value driver onto the board.
• Jul 2025 — STAY enrollment completed (1,300 dogs): de-risked execution.
• Jan 2026 — FDA accepts TAS (safety) for LOY-002: "2 of 3 sections" — the headline de-risk.
• Feb 2026 — $100M Series C (age1 lead, Baillie Gifford in): funded through launch; crossover-style entry.

Pattern: the narrative is driven by regulatory section-acceptances and trial milestones, each a discrete, countable de-risk — not by efficacy data, because the lifespan endpoint hasn't read out. That cadence is exactly what makes Loyal investable to crossover money now, and exactly the gap a skeptic attacks (Lens 13).

---

Phase C — Judge people & books (+ Science & exclusivity overlay)

Lens 9 · Management

• Celine Halioua (Founder & CEO) — neuroscience/nanobiotech (UT Austin, Uppsala), Oxford D.Phil. dropout (gene-therapy health economics), ex-Chief of Staff to Laura Deming at The Longevity Fund. Track record: founded Loyal at 25; in ~6 years took a category from nothing to the FDA's first lifespan-claim engagement, the largest vet trial in history, and ~$250M raised. Archetype: mission-driven founder-CEO — the right profile to define a category and pull longevity-believer capital; the open question is whether a first-time founder executes a regulated commercial launch and manufacturing scale-up (different muscle). Skin in the game: founder equity, undisclosed.
• Scientific / clinical bench: Loyal has built a veterinary-clinical and aging-science team and the 70-clinic STAY network; specific named C-suite (CSO/CMO/COO) not surfaced in this pass — a gap to close in diligence.
• Investor syndicate as a governance signal: Khosla, Bain Capital Ventures, Valor (Antonio Gracias), First Round, age1 (Deming), Baillie Gifford — a serious, longevity-literate cap table; Valor and Baillie Gifford bring growth/commercial discipline.

Capital-allocation history: Disciplined and sequenced to milestones — raised against RXE/TAS de-risks, took non-dilutive venture debt (Bridge Bank) to extend runway, and vertically integrated manufacturing in Denver to defend gross margin rather than outsourcing. The Series C is explicitly sized to reach launch. This is capable allocation — the bet is concentration (one company, one category, two mechanisms).

Red flags (management): (1) Single-asset, single-category concentration — Loyal is LOY-002; there is no diversified pipeline cushion. (2) First-time founder taking on commercial launch + FDA manufacturing review simultaneously — execution risk shifts from science to operations. (3) Public expectation-setting ("first FDA-approved lifespan drug," "2 of 3 sections") raises the cost of any slip. No litigation, fraud, or governance scandal found.

Lens 10 · Forensic Red Flags (+ trial-integrity / going-concern / dilution re-point)

No financial statements exist — nothing to forensically audit on the income statement, balance sheet, or cash-flow statement. The +clinical/+private re-point shifts the lens to:

• Going-concern / runway risk: undisclosed burn vs. undisclosed cash, but the $100M Series C earmarked through commercial launch materially de-risks the near-term runway versus a typical pre-revenue biotech. Still, if approval slips past the cash horizon, a down-round/markdown is the risk. No figure sourceable.
• Surrogate-endpoint / "approval ≠ proof" risk (the central forensic flag): Conditional approval rests on RXE ("reasonable expectation"), not "substantial evidence." The drug could be sold for years before STAY proves (or fails to prove) the lifespan benefit. This is a regulatory-and-evidentiary red flag, not an accounting one — but it's the one a diligence process must price.
• Mechanism-evidence gap (skeptic's forensic point): A detailed independent analysis flags that no published study demonstrates extended median lifespan in healthy wild-type mice for the LOY-002 mechanism, and that any reliance on unpublished proprietary mouse mortality data weakens the hypothesis; further, if a well-powered canine study shows significant weight loss at the LOY-002 dose, the CR-mimetic "without weight loss" claim has a problem. Treat as a sourced skeptical hypothesis, not proof of a flaw.
• Dilution risk: ~$250M raised across multiple rounds implies meaningful founder/early dilution; no audited cap table; Baillie Gifford's Series-C entry is the crossover tell but valuation undisclosed.

Regulatory findings (required sub-section):

• SEC (EDGAR LR / AAER): None possible — Loyal has no CIK; it is private and files nothing.
• Non-SEC (FTC / DOJ / FDA / consent decrees): Web search "Loyal" (FTC OR DOJ OR FDA OR settlement OR penalty OR litigation) enforcement returned no material enforcement or litigation against Loyal. To the contrary, Loyal's FDA interactions are favorable milestones (RXE/TAS acceptances), not enforcement actions.
• Item 3 (Legal Proceedings): n/a — no 10-K exists (private).
• Conclusion: No material regulatory or legal findings against Loyal — verified via SEC EDGAR EFTS (no CIK, LR/AAER = 0), web search (FTC/DOJ/FDA/litigation), and the absence of any public filing, as of 2026-06-22. Loyal's only material FDA record is the affirmative RXE/TAS technical-section acceptances. All findings unaudited per public sources.

Lens C-extra · Science & exclusivity (+clinical overlay)

• Mechanism validation:
• LOY-002 (CR-mimetic): rests on the strongest healthspan evidence in canine aging — the Purina lifetime study where calorie-restricted Labradors lived ~1.8–2 years longer with delayed cancer/osteoarthritis onset. The bet is that a drug can deliver that benefit without the food-restriction (or weight loss). Plausible and grounded, but the drug-equivalence to CR is the unproven leap.
• LOY-001/003 (IGF-1): rests on the robust body-size↔lifespan↔IGF-1 relationship in dogs (big dogs die younger; IGF-1 is the lever). Strong epidemiological basis; the leap is that lowering IGF-1 pharmacologically extends life without harm.
• Scientific credibility: grounded in mainstream geroscience (CR, IGF-1, mTOR are the field's three pillars); Loyal is pursuing the CR and IGF-1 pillars while academia (Dog Aging Project) pursues mTOR/rapamycin — Loyal is not fringe science.
• IP / exclusivity: The underlying biology (CR, IGF-1) is public domain; Loyal's exclusivity is its specific molecules/formulations, the FDA conditional-approval status (a regulatory moat), and the proprietary STAY + X-Thousand-Dogs datasets — not a blocking patent on the mechanism.
• Reimbursement/payment path: owner-pays, out-of-pocket, ~<$100/month subscription via the vet — no insurer gate required, though pet insurance (6M+ N. American policies) could expand reach. Cleaner monetization than a human drug — no payer, no formulary.

---

Phase D — Project & stress-test

Lens 11 · IPO-readiness & path-to-tradeable (+private swap for EPS) + rNPV note

No EPS projection is possible (pre-revenue). Per the +clinical overlay the question is does runway reach the next value-inflection; per +private, what unlocks a tradeable event.

• rNPV of the lead asset: n/a — not robustly sourceable. No public peak-sales anchor, no disclosed price beyond "<$100/mo," no PoS. A directional sketch only, fully labeled `` and not to be quoted as a number: the senior-dog ≥14 lb population is large (tens of millions of US dogs), and an annuity subscription at ~$1,000/yr/dog with >50% gross margin implies a potentially large revenue pool if adoption and approval land — but every input (penetration, price realization, churn, approval) is unanchored, so a point rNPV would be fabrication. Refusing to compute one.
• Runway-to-catalyst: the next inflection is CMC acceptance → XCA → first sale (late-2026/2027). The $100M Series C is explicitly sized to fund through launch, so runway-to-the-gating-catalyst looks adequately funded — the strongest single difference between Loyal and a typical pre-revenue private (which is usually runway-starved).
• IPO-readiness (no private-watch record — my judgment, scaled 1–5): ~3 ("growth/late-stage"), trending to 4 on approval. The bull tells: Baillie Gifford (a classic crossover/pre-IPO public-markets investor) entered at Series C, the company is months from potential first revenue, and it has a clean owner-pays model with no payer risk. The bear tells: it's single-asset, pre-revenue, pre-approval, and the proof (STAY lifespan readout) is years out. Milestones that unlock an S-1: (1) CMC acceptance + XCA (becomes a revenue company); (2) demonstrated commercial traction (subscriptions, vet adoption); (3) ideally interim STAY signal. Estimated tradeable window: not before 2027, and an acquisition by an animal-health major (Zoetis/Elanco/Boehringer) is at least as likely as an IPO given the distribution fit.
• Brier forecast (would-be): the scoreable binary is "Loyal obtains FDA Expanded Conditional Approval (XCA) for LOY-002, enabling US commercial sale, by 2027-12-31." My subjective p ≈ 0.55. (Per --watchlist unattended rules I do NOT run forecast.ts create; logging is a separate human-gated step.)

Write-back: Loyal has no private-watch.json entry — the +private overlay would normally set a dossier path and a readiness grade. (STRICT WAVE BOUNDARY: creating/editing registry/watchlist files is out of scope for this unattended run — flagged for the next conversational pass to add loyal to private-watch.json with stage: late, ipo_readiness: 3, catalyst "LOY-002 XCA / first FDA lifespan label", and set the dossier path.)

Lens 12 · Bull vs Bear

Bull case. Loyal is the single company about to put the words "extends lifespan" on an FDA-cleared label — for the first time in the history of any species. It built the regulatory pathway itself (RXE → TAS, two of three sections done with only manufacturing left), it owns the largest clinical dataset in veterinary history (1,300-dog STAY + 2,000-dog epigenetic corpus), it sells into a large, growing, emotionally inelastic market (people spend on dogs) through a clean owner-pays subscription with >50% gross margins and no payer/formulary friction, and it is funded through launch by a longevity-literate syndicate now including a crossover investor (Baillie Gifford). If LOY-002 reaches the shelf in 2026/27, Loyal becomes the category-defining annuity in a brand-new drug class — and the human read-through optionality (dogs as the proving ground for geroscience) is a free call option on top.

Bear case. The entire thesis rides on one not-yet-read-out trial and one not-yet-cleared manufacturing section, behind a surrogate-style approval ("reasonable expectation," not "substantial evidence") that lets the drug sell before the lifespan benefit is proven — so a null or weak STAY readout (~2028) could undercut both the science and the conditional approval after launch. The mechanism's published lifespan evidence in wild-type mammals is thinner than the marketing implies, and a documented skeptical analysis flags reliance on unpublished mouse data and a possible weight-loss confound. Loyal is single-asset and single-category — no pipeline cushion — run by a first-time founder now facing commercial-launch + FDA-manufacturing execution, and it must sell through the vet channel the incumbents (Zoetis/Elanco/Boehringer) own. Pre-revenue, pre-approval, with no tradeable instrument and no disclosed valuation.

Pre-mortem (18–24 months out, thesis broke): It's 2028. The CMC section took two extra review cycles; conditional approval slipped to 2028 and burned through the Series C, forcing a flat/down round. When STAY's lifespan data finally matured it showed a statistically soft or null effect on median lifespan (with a weight-loss signal muddying the CR-mimetic story), the FDA tightened the label, and an animal-health major that had circled walked. The lesson: a first-in-category regulatory milestone is not the same as a proven drug — Loyal monetized the pathway before the biology was confirmed, and the biology underdelivered.

Are the marks too high? n/a — no valuation disclosed. But conceptually, paying for Loyal at Series-C-implied levels is a bet on (a) approval and (b) the lifespan benefit being real — rich if you discount STAY risk, reasonable only if you believe the category and the dataset are worth a premium independent of the readout.

Contrarian view (what the market refuses to see): The consensus frame is "cute dog-longevity startup." The contrarian read is that Loyal is quietly building the regulatory and data infrastructure for geroscience itself — the first FDA lifespan pathway, validated aging biomarkers, the largest aging RCT — and the durable value may be that infrastructure/platform (licensable mechanisms, a human read-through, an animal-health-major acquisition of the category), more than any single pill's P&L. The flip-side contrarian risk: the market is under-pricing how binary the STAY readout is.

Lens 13 · Devil's Advocate (short-seller)

If I were short the eventual IPO / skeptical of the next round:

• You're selling before you've proven it works. Conditional approval is RXE ("reasonable expectation"), not substantial evidence; the lifespan endpoint reads out years after launch. The whole edifice is a bet that STAY confirms what the FDA only reasonably expects.
• The mechanism's lifespan evidence is thinner than the marketing. No published median-lifespan extension in healthy wild-type mice for the LOY-002 approach; the bull case may rely on unpublished proprietary data, and a weight-loss confound could undercut the "CR benefits without weight loss" claim.
• Single asset, single category. Loyal is LOY-002. No diversified pipeline; one trial, one manufacturing section, one regulatory category absorb essentially all the risk.
• Distribution belongs to the incumbents. Every dose goes through a vet, and Zoetis/Elanco/Boehringer own those relationships and could fast-follow with a me-too once Loyal proves the market.
• First-time-founder execution risk shifts from science (where the team is credible) to commercial launch + FDA-manufacturing review (unproven for this team).
• Surrogate-approval reversal risk: a drug on the market under conditional approval whose confirmatory trial later disappoints faces label tightening or withdrawal — a uniquely bad outcome (revenue and reputation hit simultaneously).
• "Valuation if growth disappoints": there's no public valuation to mark, but if the CMC section slips and the Series C runs short, the next round is a markdown; if STAY reads out null post-launch, the equity story (and the human read-through option) largely evaporates.
• Single scenario that permanently impairs it: STAY shows no real lifespan benefit (and/or a safety/weight-loss signal) after LOY-002 is already being sold, forcing FDA action and branding the whole "longevity drug" category as hype. Plausibility: non-trivial — that's the kill shot.

Lens 14 · Management Questions (ordered by information value)

1. What is the exact status and expected timing of the CMC/manufacturing technical section for LOY-002 — and what is your contingency if the FDA requests additional cycles? (The last gate to revenue.)
2. What does the interim STAY data show on the lifespan/healthspan endpoint, and what is the risk that the confirmatory readout (~2028) disappoints after you're already selling under conditional approval?
3. Can you point to published, well-powered evidence that the LOY-002 mechanism extends median lifespan in a healthy mammal — and how much of your effectiveness case rests on unpublished proprietary data?
4. At the LOY-002 dose, does any well-powered canine study show weight loss? How do you defend the "caloric-restriction benefits without weight loss" claim?
5. What is your current cash position and net burn, and does the Series C fund you through both XCA and commercial launch — or do you need to raise again before approval?
6. How do you win the veterinary channel against Zoetis, Elanco, and Boehringer, who own the clinic relationships and could fast-follow once you prove the market?
7. What stops an animal-health major from acquiring or out-competing you the moment LOY-002 validates the category?
8. Beyond LOY-002, how concentrated is your business — what is the realistic timeline and capital need for LOY-001/003, and what's the pipeline cushion if LOY-002 stumbles?
9. What is your IP position — what, specifically, blocks a competitor from your formulations, given CR and IGF-1 biology are public domain?
10. What is the human read-through you actually believe in, and is it a real future business or a narrative? Would you spin it out or partner it?
11. What pricing and adoption assumptions underlie your model — expected penetration of the senior-dog population, price realization, and churn on the subscription?
12. How are you building the commercial and manufacturing leadership to launch a first-in-category drug — who runs that, and what's their track record?
13. If the FDA tightens or withdraws the conditional label after a weak confirmatory readout, what is the plan for the business and the dogs already on therapy?
14. What is the single experiment or data point that would most change your own conviction in LOY-002?
15. What does an IPO vs. acquisition path look like to you, and what milestone makes the company tradeable?

---